Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"excerpt":{"rendered":"
Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"ism_preview":{"drugs":[{"title":"Palbociclib","url":"https:\/\/www.ortaakarsu.net\/?page_id=12389","facts":[{"label":"Active ingredient \/ generic name","value":"palbociclib"},{"label":"ATC code","value":"L01EF01"},{"label":"Administration route","value":"Oral"}]},{"title":"Ribociclib","url":"https:\/\/www.ortaakarsu.net\/?page_id=12403","facts":[{"label":"Active ingredient \/ generic name","value":"ribociclib"},{"label":"ATC code","value":"L01EF02"},{"label":"Administration route","value":"Oral"}]}],"record":[{"label":"Record type","value":"Published interaction record"},{"label":"Source record version","value":"EMA Ibrance SmPC; retrieved 2026-11-02; SmPC 4.2\u20134.5"}],"sources":[{"label":"IBRANCE official product information","url":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_en.pdf"},{"label":"Kisqali (ribociclib) EMA product information: regimen-dependent CYP3A inhibition","url":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf"}],"reviewed_at":"2026-11-04"},"ism_access":{"required":true,"resource_key":"pair:31046","available":true}}